Close Menu

Twist Bioscience

The companies will work together to develop new next-generation sequencing-based panels for research and diagnostics of inherited diseases.

The assay combines Twist's Human Comprehensive Exome with customized content for rare and inherited diseases from Australia-based VCGS.

In addition to discussing Twist's liquid biopsy, NGS-based genotyping and SARS-CoV-2 NGS panel, CEO Emily Leproust touted efforts on DNA data storage. 

The firm reported $28.2 million in revenues for the three months ended Dec. 31, 2020, beating consensus Wall Street estimates on the top and bottom lines.

Among firms presenting on the first day, 10x Genomics revealed it is developing a new high-throughput Chromium instrument, and Guardant plans to launch a comprehensive tissue sequencing assay.

Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.

The investment bank said that while Twist's biopharma and DNA-based data storage businesses offer upside, the timelines for generating revenues are unclear.

Pages

Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.

Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.

Science reports that a Dutch research funding agency is combating a ransomware attack.

In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.